



IDEAYA Biosciences

Improving Lives
Through Transformative
Precision Medicines

NASDAQ: **IDYA**
November 2022

IDEAYA Highlights

Breakthrough Science on transformative programs in Synthetic Lethality – an emerging area of precision medicine

Broad Pipeline of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

Proven Management Team with deep business and scientific experience has built leading oncology companies

Pharma Strategic Partnerships with GlaxoSmithKline¹, including ~\$2 billion in potential cash milestones, Pfizer² and Amgen³

Strong Balance Sheet of ~\$394 million⁴ with capital efficient model, anticipated to fund operations into 2026

Analyst Coverage by Citi, Guggenheim, Jefferies, JP Morgan, Oppenheimer, RW Baird, Stifel and Wedbush

- (1) GSK Collaboration, Option and License Agreement;
- (2) Pfizer Clinical Trial Collaboration and Supply Agreements;
- (3) Amgen Clinical Trial Collaboration and Supply Agreement;
- (4) Includes cash, equivalents and marketable securities as of September 30, 2022, pursuant to Form 10-Q filed November 8, 2022